At Alfa Chemical, a formulator once asked us: "If rebaudioside A (CAS 58543-16-1) is so safe, why does EFSA keep the acceptable daily intake so low?" It's a fair question. The safety story of Reb A is often reduced to a single number-4 mg/kg body weight per day-without context. That number comes from a rigorous assessment, but it sits alongside decades of toxicology, clinical trials, and real-world consumption data. This article walks through what the evidence actually shows, where the uncertainties lie, and how to interpret the regulatory consensus.
The regulatory picture: three agencies, one metabolite
JECFA, EFSA, and the U.S. FDA have all evaluated rebaudioside A, and they converge on the same core conclusion: high-purity Reb A is not genotoxic, not carcinogenic, and not associated with reproductive or developmental toxicity. The acceptable daily intake (ADI) of 0–4 mg/kg body weight per day, expressed as steviol equivalents, was set by JECFA and later adopted by EFSA. The FDA, meanwhile, has issued GRAS notices for Reb A with ≥95% steviol glycosides, allowing its use as a general-purpose sweetener.
The ADI is not a threshold of harm. It includes a 100-fold safety factor, applied to the highest dose at which no adverse effects were seen in a two-year rat study. In practical terms, a 70 kg adult would need to consume roughly 280 mg of steviol equivalents every day for a lifetime to reach the ADI. That is equivalent to several liters of a typical diet beverage sweetened with Reb A.
How the body handles Reb A
Reb A itself is not absorbed intact. When swallowed, it passes through the small intestine largely unchanged until it reaches the colon, where gut bacteria hydrolyze it to steviol. Steviol is the common metabolite of all steviol glycosides-stevioside, Reb A, Reb D, and others. It is then absorbed, glucuronidated in the liver, and excreted in urine and bile.
This metabolic pathway has been confirmed in both rats and humans, which is why toxicology studies on stevioside are considered relevant to Reb A. The two compounds are not identical, but they converge on the same metabolite, and the safety assessment treats them as a class.
What the animal studies actually found
The pivotal toxicology studies are not recent, but they are thorough. In a 13-week oral study in Wistar rats, the NOAEL was 50,000 ppm-roughly 4,161 mg/kg bw/day for males and 4,645 mg/kg bw/day for females. No treatment-related findings appeared in organ histopathology, including testes and kidneys. A 4-week study found a NOAEL of 100,000 ppm.
For fermentation-derived Reb A, a 91-day study in Sprague–Dawley rats found no adverse effects at doses up to 2,057 mg/kg bw/day (males) and 2,023 mg/kg bw/day (females). These NOAELs are several orders of magnitude above the ADI, which is why the 100-fold safety factor is considered conservative.
A 2025 immunohistochemical study looked specifically at acetylcholinesterase-positive neurons in the rat brain cortex after Reb A exposure. No significant morphological changes were observed, adding to the evidence that Reb A lacks neurotoxic potential at relevant doses.
The EFSA review: why the ADI did not increase
In 2024, EFSA evaluated a proposal to raise the ADI to 6 or 16 mg/kg bw/day. The Panel declined, citing insufficient justification. One key reason: conservative exposure estimates for toddlers already exceeded the current ADI at the 95th percentile. That does not mean Reb A is unsafe for toddlers-it means the margin of safety is narrower for that subgroup, and EFSA chose to keep the ADI conservative until more data are available.
For formulators, this is a practical consideration. If your product is intended for children, you may want to keep Reb A levels below the ADI, or blend it with other sweeteners to reduce total steviol equivalent intake.
Degradation products: a nuance worth knowing
Under acidic conditions-such as in carbonated beverages-Reb A can degrade. A 2025 LC-HRMS/MS study characterized these degradation products and estimated their toxicity. Most were classified as moderately toxic (Class 4), while one (DP-3) was non-toxic. All base degradation products were non-toxic. The practical takeaway: under normal storage and use, degradation products are not a significant safety concern, but if you are formulating a low-pH beverage with a long shelf life, it is worth monitoring.
Human data: what clinical studies show
Clinical studies on purified Reb A have found no effect on blood pressure or glucose homeostasis in human subjects. This is important for diabetic-friendly products: Reb A does not raise blood sugar. Some research even suggests that steviol glycosides may enhance insulin secretion and improve insulin sensitivity, although these findings are preliminary and not the basis for safety claims.
For pregnant women, EFSA's review found no evidence of reproductive or developmental toxicity. The ADI is considered protective, but as with any sweetener, individual medical advice should come from a healthcare provider.
China's regulatory framework
In China, steviol glycosides are regulated under GB 1886.355-2022, which applies to products extracted and refined from Stevia rebaudiana leaves. The standard requires a minimum of 90% steviol glycosides on a dry basis and specifies HPLC as the analytical method. Reb A is one of the recognized glycosides within this standard. For export-oriented manufacturers, this aligns with JECFA and EFSA specifications.
Safety summary
| Endpoint | Finding |
|---|---|
| Acute toxicity | LD₅₀ > 15 g/kg bw (low acute toxicity) |
| Genotoxicity | Negative in standard test battery |
| Carcinogenicity | No treatment-related tumors in 2-year rat study |
| Reproductive toxicity | No evidence of developmental or reproductive effects |
| ADI (JECFA/EFSA) | 0–4 mg/kg bw/day (as steviol equivalents) |
| FDA status | GRAS for general-purpose sweetener use |
| China status | Regulated under GB 1886.355-2022 |
Frequently asked questions
Q: If Reb A is safe, why is the ADI so low?
The ADI is a conservative estimate that includes a 100-fold safety factor. It is not a threshold of harm. Typical consumption is far below the ADI, except possibly in young children who drink large amounts of sweetened beverages. For our Reb A product specifications, see our product page.
Q: Does fermentation-derived Reb A have the same safety profile?
Yes. JECFA confirmed in 2016 that fermentation-derived Reb A falls under the same ADI, provided it meets the same purity specifications. The FDA has also reviewed fermentation-derived Reb A and found no adverse effects in a 91-day rat study.
Q: Can Reb A cause cancer?
No. EFSA and JECFA both concluded that steviol glycosides are not carcinogenic. The two-year rat study showed no treatment-related tumors at doses well above the ADI.
Q: Is Reb A safe for diabetics?
Clinical studies show no effect on blood glucose or insulin levels. Reb A is a zero-calorie sweetener and does not raise blood sugar. If you are evaluating Reb A for a diabetic-friendly formulation, our steviol glycosides portfolio includes Reb A, Reb M, and Reb D for different sweetness profiles.
Q: What about degradation products in acidic drinks?
A 2025 study found that most acid degradation products are moderately toxic in silico, but under normal storage conditions they do not pose a significant safety concern. If you are developing a low-pH beverage with a long shelf life, stability testing is recommended.
About Alfa Chemical
Alfa Chemical is a China-based manufacturer of steviol glycosides, biochemicals, and specialty intermediates. Since 2018, we have supplied high-purity Rebaudioside A (CAS 58543-16-1) and related sweetener ingredients to food, beverage, and pharmaceutical customers in over 50 countries. Our Zhengzhou facility operates under ISO 9001 and supports full documentation for regulatory submissions.
Need Reb A Specifications or a Sample?
If you are evaluating Rebaudioside A for a food, beverage, or pharmaceutical application, our technical team can provide:
📄 Batch-specific COA - assay, specific rotation, heavy metals
📋 Regulatory documentation - for JECFA, EFSA, FDA, or GB submissions
🧪 Research samples - for formulation development and stability testing
Email: sales07@alfachem.cn
Phone: +86-371-55052911